A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer.

BLI tracking over the course of the experiment demonstrated that tumor load between the three groups started segregating around day 30, with maximal differences noted at about day 47, with the CAM1615HER2 TriKE demonstrating highly significant and superior tumor control ( Figure 6 C,D).

also in 132,142 other papers